Diagnostic information from the profile was compared to that from cholesterol and triglycerides alone or from the Medicare-approved panel. National Cholesterol Education Program (NCEP) guidelines were used to determine cutpoints. As a minimum standard, utility was defined as providing new information in the form of reclassifying a patient from desirable to undesirable by the addition of analytes to a lipid profile.
Little was gained by adding Apo A1 and Apo B100 to the Medicare-approved lipid panel. Lipoprotein(a) measurements do not correlate with any of the Medicare panel components and significant elevations are prevalent in patients with desirable cholesterol and triglyceride levels. Low Lp(a) values are associated with elevated VLDLc. Lipoprotein electrophoresis is useful to screen for intermediate bands.
Background
Laboratory professionals are often faced with the challenge of designing profiles or groupings of tests that would best serve clinicians treating a given patient population. Foremost is the need for determining the optimum test-grouping or profile that would serve to screen the general population for dyslipidemias. Dyslipidemias that contribute to increased risk for coronary heart disease (CHD) are conditions that satisfy all the major requirements for warranting wide-spread screening programs. That is, dyslipidemia is silent, prevalent, associated with high morbidity and mortality, treatable with proven benefit, and can be detected nearly non-invasively and relatively inexpensively. The question that remains is what comprises the optimum lipid screen for assessing risk in the general outpatient population. Because the role of various lipid-related analytes in contributing to risk for atherosclerosis has yet to be definitively determined, the goal of designing an optimum lipid profile is challenging. However, at a minimum, this can be addressed by determining the likelihood of obtaining new information based on correlation of components and prevalence of abnormalities when analytes are added to abbreviated lipid screens.
The Medicare approved panel consists of total cholesterol (TC), triglycerides (TG), LDLc-cholesterol (LDLc), and HDLc-cholesterol (HDLc); and provides sufficient information for clinicians following NCEP guidelines for patient care. 1 As an initial screen, the Medicare panel with a calculated TC/HDLc risk ratio is in widespread use. However, the prevalence of CHD in patients with desirable lipid profiles as measured by this screen indicates the need for a more sensitive and specific approach. 2 Additional lipid-related analytes have been proposed as significant markers for cardiovascular risk. Among these are the apolipoproteins A1 and B100, 3, 4 Lp(a), [5] [6] [7] [8] intermediate density lipoprotein (IDL), 9,10 remnant like particle (RLP) assays, 8, [11] [12] [13] and LDLc or HDLc subclasses. [14] [15] [16] The facility with which a laboratory can incorporate these analytes into routine use depends on the methodology and technical expertise available. Immunoassays for Lp(a) and apolipoproteins are readily available; methods for LDLc and HDLc subclasses, IDL, and RLP assays are generally restricted to fewer laboratories or are under development. Lipoprotein electrophoresis, however, may be used to screen for abnormal patterns including the presence of intermediate mobility bands.
This study was undertaken to evaluate the additional information provided by an expanded lipid profile in contrast to that provided by the Medicare-approved lipid screen. This was measured by the prevalence of abnormalities in the expanded panel in the setting of a normal screen. For this medium-sized hospital in an academic setting but without a specialized lipid laboratory, the expanded lipid profile consists of the lipid screen above plus Apo A1, Apo B100, Lp(a), and a screen for broadbeta or intermediate mobility bands by lipoprotein electrophoresis. The results obtained in 265 consecutive outpatients for which lipid testing was requested were evaluated for the number and types of dyslipidemia that were found by the expanded profile which would have been missed by the Medicare-approved screen alone.
Materials and Methods
The study was performed as a retrospective review of laboratory data and was approved by the institution's research conduct administration. All specimens had been collected and processed for routine clinical purposes. Other than lipid results, data available included only age and sex.
Data was collected from 266 consecutive comprehensive lipid profiles ordered science [chemistry] on outpatients. Data from one patient (3 years old) was omitted since pediatric reference values were not used for analysis. All analytes except the apolipoproteins were measured using a Beckman LX20 (Beckman Coulter M, Fullerton, CA). Total cholesterol and triglycerides were measured enzymatically, and HDLc was measured by the Genzyme Liquid N-geneous assay (Genzyme M, Cambridge, MA). LDLc was calculated when TG<400 mg/dL (4.52 mmol/L) using VLDLc = TG/5. For patients with TG ≥ 400 mg/dL, a direct LDLc measurement (Equal Diagnostics M, Exton, PA) was obtained in lieu of the calculated LDLc. Lipoprotein(a) was measured by immunoprecipitation (DiaSorin M, Stillwater, MN). Apo A1 and Apo B100 were measured nephelometrically on the Beckman Array. Lipoprotein electrophoresis was performed using the Beckman Paragon system. A total cholesterol to HDLc risk factor was calculated, along with an ApoA1/ApoB100 ratio.
Recent revisions to NCEP guidelines 1 were used to classify patient results. Total cholesterol was defined as desirable, borderline or high using intervals of <200 mg/dL (5.18 mmol/L), 200-239 mg/dL, and >240 mg/dL (6.22 mmol/L) respectively. Triglycerides were normal, borderline high, or very high using intervals of <150 mg/dL (1.7 mmol/L), 200-499 mg/dL, and >500 mg/dL (5.6 mmol/L). LDLc cut-points were 130 (3.4), 160 (4.1), and 190 (4.9) mg/dL (mmol/L); VLDLc was defined as normal if <30mg/dL (0.34 mmol/L); desirable HDLc was defined as >40 mg/dL. For Lp(a), desirable was defined as <30 mg/dL.
Results
Of the 265 of 266 subjects (1 baby was excluded), 153 (58%) were male, 111 (42%) were female, and 1 subject had no sex specified. Ages ranged from 18 years to 92 years with a mean age of 56 years (SD 16); 6 of the subjects did not have an age specified. Laboratory data was incomplete for 8 of the subjects for which apolipoprotein results were not available.
Forty-five percent of the subjects (120) had cholesterol less than 200 mg/dL and TG less than 150 mg/dL; and thus, would be classified as having desirable values.
The distribution of Lp(a) was similar for subjects with normal cholesterol and TG compared to all subjects [F1]. The distribution is skewed to the right with a median value for all subjects of 26.5 mg/dL which is comparable to that obtained in other studies (see for example Figure 1 in reference 17 
Discussion
From this study, a lipid screen consisting of total cholesterol and triglycerides can be used reliably to rule out elevated LDLc in patients with less than 2 major risk factors since none of the patients with normal cholesterol had LDLc >160 mg/dL. The screen also serves to identify undesirable LDLc levels in patients with more than 1 risk factor but without CHD or risk equivalents because only 4% of the patients with normal cholesterol and triglycerides had LDLc >130. The screen is inadequate for adjusting risk factors based on HDLc since 40% of the normal subjects were found to have HDLc <40 mg/dL. For Apo B100, a cutoff of 103 mg/dL, the laboratory upper reference value, was used for the presentation of the data. However, in this study, an LDLc value of 160 mg/dL corresponds to an Apo B100 value of >125 mg/dL [F3B] . No patients with desirable cholesterol and triglycerides were found to have Apo B100 levels >125 mg/dL. Similarly, the diagnostic performance of the screen for assessing low Apo A1 depends on the cutoff chosen. An HDLc cutoff of 40 mg/dL corresponds to approximately 110 mg/dL for Apo A1 [F3A].
Adding Apo B100 and Apo A1 to the Medicare-approved panel provided little additional information when cutoffs for these analytes that correspond to NCEP LDLc and HDLc cut-points were used. In addition, the risk ratio as determined by TC/HDLc was significantly correlated with the Apo A1/Apo B100 risk ratio. In conclusion, for screening purposes, little diagnostic information is gained by adding Apo A1 and Apo B100 to the Medicare-approved lipid panel. Lp(a) measurements do not correlate with any of the Medicare panel components and significant elevations are prevalent in patients with desirable cholesterol and triglyceride levels. Hence, a direct measurement of Lp(a) should be included in a screening lipid profile. Lipoprotein electrophoresis is useful to screen for intermediate bands.
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Low Lp(a) measurements are significantly associated with VLDLc values >30 mg/dL. Recognition of this subphenotype of type IV hyperlipoproteinemia is important for risk assessment. 
